Grahams Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 15-12-2024
- Paid Up Capital ₹ 1.00 M
as on 15-12-2024
- Company Age 6 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.85 Cr
as on 15-12-2024
- Revenue 147.41%
(FY 2022)
- Profit 19.55%
(FY 2022)
- Ebitda 5.79%
(FY 2022)
- Net Worth 186.46%
(FY 2022)
- Total Assets 70.86%
(FY 2022)
About Grahams Pharmaceuticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹4.85 Cr.
Stephen Devassy, Lito Baby, Lijo Baby, and One other member serve as directors at the Company.
- CIN/LLPIN
U51909KL2018PTC053129
- Company No.
053129
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 May 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Ernakulam, Kerala, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Grahams Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Lijo Baby  | Managing Director | 02-May-2018 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Stephen Devassy | Director | 02-May-2018 | Current |
| Lito Baby | Director | 02-May-2018 | Current |
| Mini Varghese | Director | 02-May-2018 | Current |
Financial Performance of Grahams Pharmaceuticals.
Grahams Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 147.41% increase. The company also saw a substantial improvement in profitability, with a 19.55% increase in profit. The company's net worth Soared by an impressive increase of 186.46%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Grahams Pharmaceuticals?
In 2021, Grahams Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Ethan Packers Private LimitedActive 11 years 5 months
Stephen Devassy, Lito Baby and 2 more are mutual person
- Grafiqe Printers Private LimitedActive 6 years 10 months
Stephen Devassy, Lito Baby and 2 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 02 Feb 2023 | ₹3.50 M | Open |
State Bank Of India Creation Date: 23 Jun 2021 | ₹4.50 Cr | Open |
How Many Employees Work at Grahams Pharmaceuticals?
Unlock and access historical data on people associated with Grahams Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Grahams Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Grahams Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
